Turn Therapeutics Refines GX-03 Eczema Trial After Interim Data, Eyes 2026 Readout

Turn Therapeutics Refines GX-03 Eczema Trial After Interim Data, Eyes 2026 Readout Written by MarketBeat July 11, 2026 Share Link copied to clipboard. Image from MarketBeat Media, LLC. Key Points Turn Therapeutics refined the stage two design of its GX-03 phase II eczema trial after an interim analysis of the first 50 completers, using a staged adaptive approach without pausing enrollment. The interim data suggested stronger responses in patients with lower EASI scores and higher baseline itch, leading the company to enrich stage two by requiring a PP-NRS itch score of at least 7 and stratifying patients by EASI severity. Turn said GX-03 has shown a favorable safety profile so far, with no treatment-related serious adverse events, and expects a stage two readout in Q4 2026 before discussing phase III plans with the FDA. Five stocks we like better than Turn Therapeutics . Turn Therapeutics NASDAQ: TTRX outlined the final stage two design and data-driven expansion of its GX-03 phase II program in atopic dermatitis during an investor update call, saying the revised approach was informed by an interim analysis of the first 50 completers in the ongoing trial. Brad Burnam, founder and chief executive officer of Turn Therapeutics, said the company used a staged adaptive study design to refine the second stage without pausing enrollment. He described the approach as a way to use data from the company’s own trial population to improve the next stage while maintaining trial integrity under the oversight of a Data Monitoring Committee. Get Turn Therapeutics alerts: Sign Up “The trial remains ongoing. Enrollment did not pause throughout this interim review period,” Burnam said. He added that the company believes the staged design offers “a higher probability of success” because it uses the same population, investigators and patient population as the initial stage. Interim Analysis Expands Focus Beyond Initial EASI Threshold Burnam spent part of the presentation explaining the d...